FDA Solicits Public Comments on Use of Cannabis-Derived Products in Veterinary Medicine

The U.S. Food and Drug Administration’s Center for Veterinary Medicine has released a request for information (RFI) soliciting comments from the public, particularly veterinarians, related to the use of cannabis-derived products (CDP) in animals. The focus of this RFI is on cannabidiol (CBD) products and other products derived from hemp. The FDA is interested in general trends associated with these products, such as information about usage trends (e.g., product selection, indications, etc.), quality standards, benefits of use, potential drug interactions, adverse events and safety problems, and toxicological concerns.

Information received through this RFI will enhance the FDA’s knowledge of potential safety signals associated with CDPs and improve the FDA’s understanding of veterinarians’ experiences related to the use of CDPs in their animal patients.

The Federal Register notice about the RFI contains instructions for submitting comments. The FDA will fully consider all comments, including comments submitted anonymously if someone does not wish to provide their name along with their submission. The specific questions in the RFI are intended to guide the public, particularly veterinarians, in providing the information that will be most helpful to the FDA. The comment period for this RFI opens on January 16, and will be open for 90 days, ending on April 16, 2025.

For more information: FDA Solicits Public Comments on Use of Cannabis-Derived Products in Veterinary Medicine.